Corgenix Medical (OTCQB:CONX) reported financial results for the fiscal second quarter ending December 31, 2013. Results were largely in-line but slightly better than our estimates. Particularly noteworthy was relative q-to-q strength in international sales. While international sales fell 18% on a y-o-y basis, they showed a nice rebound sequentially, jumping more than 100% from Q1. As we noted in our previous update, we had expected international sales to firm up throughout the remainder of fiscal 2014.
CONX continues to grow both the top-line as well as margins with gross margins continuing to exhibit greater strength with a higher volume of sales. Similar to the previous four quarters, gross margin was relatively strong and better than our estimate. Management's
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|